UOC
PCVX icon

UBS O'Connor’s Vaxcyte PCVX Stock Holding History

UBS O'Connor’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,307
Closed -$606K – 534
2024
Q3 		$606K Sell
5,307
-1,000
-16% -$90.1K 0.02% 331
2024
Q2 		$476K Buy
6,307
+300
+5% +$20.4K 0.01% 369
2024
Q1 		$410K Sell
6,007
-2,023
-25% -$140K 0.01% 346
2023
Q4 		$504K Sell
8,030
-1,970
-20% -$102K 0.02% 348
2023
Q3 		$510K Buy
+10,000
New +$493K 0.01% 400
2023
Q2 		– Sell
-8,071
Closed -$303K – 628
2023
Q1 		$303K Buy
+8,071
New +$342K 0.01% 497

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS O'Connor's PCVX Position: Q4 2024 in Review

UBS O'Connor sold out of Vaxcyte (PCVX) in Q4 2024, closing a stake of 5,307 shares — an estimated $606K sold.

UBS O'Connor first reported a position in PCVX in Q1 2023 and held it in 6 quarters. The position peaked at $606K in Q3 2024. 323 funds tracked by Wall St. Rank hold PCVX as of Q4 2024.

  • UBS O'Connor reported no remaining Vaxcyte position as of Q4 2024 after selling out during the quarter.
  • UBS O'Connor sold 5,307 Vaxcyte shares in Q4 2024, an estimated $606K.
  • UBS O'Connor first reported a position in Vaxcyte in Q1 2023 and held it in 6 quarters.
  • UBS O'Connor's Vaxcyte position peaked at $606K in Q3 2024.
  • 323 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2024.

Based on UBS O'Connor's 13F filing for Q4 2024, filed 14 Feb 2025.